A Phase 2/3 interventional study of HRS8179 injection and HRS8179 blank preparation. in Severe Cerebral Edema Following Large Hemispheric Infarction, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Brain Edema with a site in China — 7 open to participants now, 7 under way, 1 of them phase 3. Brain Edema · China.
Among the 23 studies in Brain Edema with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2/3, and was the 20th registered.
102 studies on the registry are indexed under Brain Edema; 25 are open to participants now.
Browse Brain Edema studies →7 of the 23 studies in Brain Edema with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–75
Zhejiang Provincial People's Hospital · Sites in China
Ages 18–80
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–79
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 20–80
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Brain Edema studies recruiting now, 2 (20%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 3
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 725 is above the median of 60 across 62 interventional studies indexed under Brain Edema.
Median enrollment 100 across the 15 interventional studies, 114 across the 8 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 2 studies filed under Brain Edema — fewer than ten, so there is no comparison to draw.
3 of the studies in Brain Edema with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06732648Phase 3Beijing Suncadia Pharmaceuticals Co., LtdThe Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction | 2027-06 |
| NCT06451887Zhejiang Provincial People's HospitalEarly Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study) | 2027-03 |
| NCT07528456Nanfang Hospital, Southern Medical UniversityButylphthalide for Brain Edema After Endovascular Treatment | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Brain Edema with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS8179 injection
Drug: HRS8179 injection
Drug: HRS8179 blank preparation.
HRS8179 injection; high dose
HRS8179 blank preparation.
Mortality rate at Day 90
Time frame: at Day 90
The modified Rankin Scale (mRS) score at Day 90
Time frame: at Day 90
The proportion of participants who achieved mRS score 0-4 at Day 90
Time frame: at Day 90
Changes in midline shift from baseline to 72 hours
Time frame: from baseline to 72 hours
The proportion of participants who meet the indications for decompressive craniectomy by Day 14
Time frame: Day 14
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Suncadia Pharmaceuticals Co., Ltd →